Thema immunotherapy

A pioneer of IMMUCOTHEL has passed

A pioneer of IMMUCOTHEL has passed

The urologist Karl-Friedrich Klippel was intensely focused on bladder cancer. He has now died at the age of 76. biosyn Arzneimittel GmbH will always hold his name in honorable remembrance. At our biotechnology corporation, the former president of the German non-profit Society of Biological Cancer Defense (Gesellschaft für Biologische Krebsabwehr e.V.) was a major force driving the development of and providing scientific support for IMMUCOTHEL, our drug for the management of superficial carcinoma of the urinary bladder, also referred to as non-muscle-invasive bladder cancer (NMIBC).

Read more...

A tale of two subunits: KLH 1 and KLH 2 in Immucothel

A tale of two subunits: KLH 1 and KLH 2 in Immucothel

Themes of earthly duality have been inspirations throughout history, for example, compelling Charles Dickens to write about two contrasting cities, Goethe’s character Faust to lament the two competing souls in his breast and Shakespeare’s Hamlet to confront the choice between life and death. The exploration of dichotomies by novelists and poets has produced great works of literature and expanded our insights into the human situation. The same holds true for researchers and science.

Read more...

KLH to fight the disease of forgetfulness: Researchers closing in on a vaccine

KLH to fight the disease of forgetfulness: Researchers closing in on a vaccine

The memory loss disorder eponymously called Alzheimer's burdens around 44 million people worldwide, according to the statistics reported by “Alzheimer’s News Today”. The prevalence of this neurodegenerative disease is as pathologically progressive as is its clinical course. Absent any cure or any way to stop or slow progression, the only options are symptomatic treatments and coping strategies for patients and their loved ones. Therefore, many committed researchers have long set their sights on developing a vaccine to ward off the disease’s neurodegenerative mental decline.

Read more...

Hope is the color blue. The unique IMMUCOTHEL® from the keyhole limpet indicated for the prevention of superficial bladder cancer recurrence.

What to do when the standard fails? Wasn't it enough that the patient suffered from superficial bladder cancer and now a post-TUR recurrence? After standard therapies were contraindicated, have been exhausted or were not tolerated in the first place, second-line treatment with IMMUCOTHEL® is indicated to prevent recurrences in superficial bladder cancer. This immunotherapeutic from biosyn is a safe, efficacious and well-established alternative to BCG. Thanks to its high tolerability and low rate of side effects, patients experience much less distress with IMMUCOTHEL®.

Read more...